Active Pharmaceutical Ingredients (APIs)

Our R&D team has developed optimized and efficient processes to ensure the consistent and reliable production of high-quality Active Pharmaceutical Ingredients (APIs). With a strong focus on innovation and compliance, we support global pharmaceutical markets with trusted API solutions designed for performance and scalability.

Intermediates

Leveraging our backward-integrated manufacturing systems, we supply premium-grade pharmaceutical intermediates that meet international quality standards. Our integrated approach ensures a dependable supply chain, supporting seamless progression from intermediate to finished API.

CDMO

Symbio’s CDMO platform is built for partners who value science, speed, and substance. Our strength lies in transforming challenging chemistry into commercially viable, environmentally conscious processes through deep expertise in process optimization, green chemistry, and enzymatic synthesis. With a state-of-the-art R&D centre, peptide capabilities, and three advanced manufacturing sites - including our Vizag facility awaiting USFDA/EUGMP audits - Symbio bridges early development and large-scale production with agility and precision. The company’s infrastructure supports everything from low-volume, high-potency projects to high-throughput commercial batches, all within a framework of strong regulatory and ESG discipline.

Backed by a 20-acre expansion land bank, Symbio partners with global innovators to co-create next-generation APIs and intermediates—where science meets scalability and sustainability drives differentiation.